Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

March 31, 2007

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Gemcitabine, Carboplatin, Bevacizumab

Patients will be treated with Gemcitabine 2000mg/m\^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.

Trial Locations (2)

55422

Hubert H. Humphrey Cancer Center, Minneapolis

55455

University of Minnesota Cancer Center, Minneapolis

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Masonic Cancer Center, University of Minnesota

OTHER